A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
At a glance
- Drugs Lifileucel (Primary) ; LN 145 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Head and neck cancer; Large cell carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 02 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Nov 2018 to 1 Jan 2019.
- 06 Nov 2018 According to an Iovance Biotherapeutics media release, there are currently two sites active for this trial.
- 18 Oct 2018 According to an Iovance Biotherapeutics media release, he company is planning to start this trial in Europe and have received approval from the Medicines and Healthcare products Regulatory Agency (MHRA).